Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients.
Van Wigcheren GF, De Haas N, Mulder TA, Horrevorts SK, Bloemendal M, Hins-Debree S, Mao Y, Kiessling R, van Herpen CML, Flórez-Grau G, Hato SV, De Vries IJM. Van Wigcheren GF, et al. Among authors: bloemendal m. Oncoimmunology. 2021 Jun 27;10(1):1935557. doi: 10.1080/2162402X.2021.1935557. eCollection 2021. Oncoimmunology. 2021. PMID: 34239773 Free PMC article.
Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy.
Bloemendal M, van Willigen WW, Bol KF, Boers-Sonderen MJ, Bonenkamp JJ, Werner JEM, Aarntzen EHJG, Koornstra RHT, de Groot JWB, de Vries IJM, van der Hoeven JJM, Gerritsen WR, de Wilt JHW. Bloemendal M, et al. Ann Surg Oncol. 2019 Nov;26(12):3945-3952. doi: 10.1245/s10434-019-07274-2. Epub 2019 Mar 4. Ann Surg Oncol. 2019. PMID: 30830540 Free PMC article.
Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial.
Boudewijns S, Bloemendal M, de Haas N, Westdorp H, Bol KF, Schreibelt G, Aarntzen EHJG, Lesterhuis WJ, Gorris MAJ, Croockewit A, van der Woude LL, van Rossum MM, Welzen M, de Goede A, Hato SV, van der Graaf WTA, Punt CJA, Koornstra RHT, Gerritsen WR, Figdor CG, de Vries IJM. Boudewijns S, et al. Among authors: bloemendal m. Cancer Immunol Immunother. 2020 Mar;69(3):477-488. doi: 10.1007/s00262-019-02466-x. Epub 2020 Jan 24. Cancer Immunol Immunother. 2020. PMID: 31980913 Free PMC article. Clinical Trial.
The tumour microenvironment shapes dendritic cell plasticity in a human organotypic melanoma culture.
Di Blasio S, van Wigcheren GF, Becker A, van Duffelen A, Gorris M, Verrijp K, Stefanini I, Bakker GJ, Bloemendal M, Halilovic A, Vasaturo A, Bakdash G, Hato SV, de Wilt JHW, Schalkwijk J, de Vries IJM, Textor JC, van den Bogaard EH, Tazzari M, Figdor CG. Di Blasio S, et al. Among authors: bloemendal m. Nat Commun. 2020 Jun 2;11(1):2749. doi: 10.1038/s41467-020-16583-0. Nat Commun. 2020. PMID: 32488012 Free PMC article.
Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination.
van Willigen WW, Bloemendal M, Boers-Sonderen MJ, de Groot JWB, Koornstra RHT, van der Veldt AAM, Haanen JBAG, Boudewijns S, Schreibelt G, Gerritsen WR, de Vries IJM, Bol KF. van Willigen WW, et al. Among authors: bloemendal m. Oncoimmunology. 2020 Mar 22;9(1):1738814. doi: 10.1080/2162402X.2020.1738814. Oncoimmunology. 2020. PMID: 33457087 Free PMC article.
Immunological responses to adjuvant vaccination with combined CD1c+ myeloid and plasmacytoid dendritic cells in stage III melanoma patients.
Bloemendal M, Bol KF, Boudewijns S, Gorris MAJ, de Wilt JHW, Croockewit SAJ, van Rossum MM, de Goede AL, Petry K, Koornstra RHT, Figdor C, Gerritsen WR, Schreibelt G, de Vries IJM. Bloemendal M, et al. Oncoimmunology. 2021 Dec 30;11(1):2015113. doi: 10.1080/2162402X.2021.2015113. eCollection 2022. Oncoimmunology. 2021. PMID: 36524210 Free PMC article. Clinical Trial.
Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial.
Bol KF, Schreibelt G, Bloemendal M, van Willigen WW, Hins-de Bree S, de Goede AL, de Boer AJ, Bos KJH, Duiveman-de Boer T, Olde Nordkamp MAM, van Oorschot TGM, Popelier CJ, Pots JM, Scharenborg NM, van de Rakt MWMM, de Ruiter V, van Meeteren WS, van Rossum MM, Croockewit SJ, Koeneman BJ, Creemers JHA, Wortel IMN, Angerer C, Brüning M, Petry K, Dzionek A, van der Veldt AA, van Grünhagen DJ, Werner JEM, Bonenkamp JJ, Haanen JBAG, Boers-Sonderen MJ, Koornstra RHT, Boomsma MF, Aarntzen EHJ, Gotthardt M, Nagarajah J, de Witte TJM, Figdor CG, de Wilt JHW, Textor J, de Groot JWB, Gerritsen WR, de Vries IJM. Bol KF, et al. Among authors: bloemendal m. Nat Commun. 2024 Feb 23;15(1):1632. doi: 10.1038/s41467-024-45358-0. Nat Commun. 2024. PMID: 38395969 Free PMC article. Clinical Trial.
Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy.
Bloemendal M, Rietveld MJA, van Willigen WW, Gerritsen WR, Figdor CG, Bonenkamp JJ, Westdorp H, Boudewijns S, Koornstra RHT, Adang EMM, Schreibelt G, Ottevanger PB, de Vries IJM, Bol KF. Bloemendal M, et al. Clin Transl Oncol. 2019 Jun;21(6):774-780. doi: 10.1007/s12094-018-1987-0. Epub 2018 Nov 21. Clin Transl Oncol. 2019. PMID: 30465182
46 results